Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+‐activated K+ channels

C Hougaard, BL Eriksen, S Jørgensen… - British journal of …, 2007 - Wiley Online Library
C Hougaard, BL Eriksen, S Jørgensen, TH Johansen, T Dyhring, LS Madsen, D Strøbaek…
British journal of pharmacology, 2007Wiley Online Library
Background and purpose: Positive modulators of small conductance Ca2+‐activated K+
channels (SK1, SK2, and SK3) exert hyperpolarizing effects that influence the activity of
excitable and non‐excitable cells. The prototype compound 1‐EBIO or the more potent
compound NS309, do not distinguish between the SK subtypes and they also activate the
related intermediate conductance Ca2+‐activated K+ channel (IK). This paper
demonstrates, for the first time, subtype‐selective positive modulation of SK channels …
Background and purpose
Positive modulators of small conductance Ca2+‐activated K+ channels (SK1, SK2, and SK3) exert hyperpolarizing effects that influence the activity of excitable and non‐excitable cells. The prototype compound 1‐EBIO or the more potent compound NS309, do not distinguish between the SK subtypes and they also activate the related intermediate conductance Ca2+‐activated K+ channel (IK). This paper demonstrates, for the first time, subtype‐selective positive modulation of SK channels.
Experimental approach
Using patch clamp and fluorescence techniques we studied the effect of the compound cyclohexyl‐[2‐(3,5‐dimethyl‐pyrazol‐1‐yl)‐6‐methyl‐pyrimidin‐4‐yl]‐amine (CyPPA) on recombinant hSK1‐3 and hIK channels expressed in HEK293 cells. CyPPA was also tested on SK3 and IK channels endogenously expressed in TE671 and HeLa cells.
Key results
CyPPA was found to be a positive modulator of hSK3 (EC50 = 5.6 ± 1.6 μM, efficacy 90 ± 1.8 %) and hSK2 (EC50 = 14 ± 4 μM, efficacy 71 ± 1.8 %) when measured in inside‐out patch clamp experiments. CyPPA was inactive on both hSK1 and hIK channels. At hSK3 channels, CyPPA induced a concentration‐dependent increase in the apparent Ca2+‐sensitivity of channel activation, changing the EC50(Ca2+) from 429 nM to 59 nM.
Conclusions and implications
As a pharmacological tool, CyPPA may be used in parallel with the IK/SK openers 1‐EBIO and NS309 to distinguish SK3/SK2‐ from SK1/IK‐mediated pharmacological responses. This is important for the SK2 and SK1 subtypes, since they have overlapping expression patterns in the neocortical and hippocampal regions, and for SK3 and IK channels, since they co‐express in certain peripheral tissues.
British Journal of Pharmacology (2007) 151, 655–665; doi:10.1038/sj.bjp.0707281
Wiley Online Library